Search results for "PHASE-I"

showing 6 items of 16 documents

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

2016

AIM To study the tolerance and the efficiency of FOLFIRINOX in elderly patients diagnosed with colorectal or pancreatic cancer. METHODS This retrospective study included elderly patients aged over 70 years of age treated at Georges-Francois Leclerc Center by FOLFIRINOX for histological proved colorectal or pancreatic cancer between January 2009 and January 2015. Chemotheapy regimen consisted of oxaliplatin (85 mg/m(2) in over 120 min) followed by leucovorin (400 mg/m(2) in over 120 min), with the addition, after 30 min of irinotecan (180 mg/m(2) in over 90 min) then 5 fluorouracil (5FU) (400 mg/m(2) administred intravenous bolus), followed by 5FU (2400 mg/m2 intraveinous infusion over 46 h)…

MaleTime FactorsOrganoplatinum CompoundsColorectal cancerFOLFIRINOXLeucovorinPooled AnalysisInternational-SocietyKaplan-Meier EstimateOlder PatientsGastroenterology0302 clinical medicineRisk FactorsAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicineAged 80 and overAge FactorsGastroenterologyCommon Terminology Criteria for Adverse EventsGeneral Medicine3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisDisease ProgressionFolfirinoxFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFluorouracilFranceFolfirinox RegimenColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyOxaliplatin FolfirinoxIrinotecanDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesPancreatic CancerRetrospective StudyInternal medicinePancreatic cancermedicineHumansChemotherapyGeriatric AssessmentAgedRetrospective StudiesColorectal CancerChi-Square DistributionPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyElderly Patientsmedicine.diseasePhase-Ii Trial1st-Line TreatmentSurgeryPancreatic NeoplasmsIrinotecanRegimenMultivariate AnalysisCamptothecinOpen-LabelFeasibility TreatmentTomography X-Ray Computedbusiness
researchProduct

Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

2012

T lymphocytes are often induced naturally in melanoma patients and infiltrate tumors. Given that gamma delta T cells mediate antigen-specific killing of tumor cells, we studied the representation and the in vitro cytokine production and cytotoxic activity of tumor infiltrating gamma delta T cells from 74 patients with primary melanoma. We found that gamma delta T cells represent the major lymphocyte population infiltrating melanoma, and both V delta 1(+) and V delta 2(+) cells are involved. The majority of melanoma-infiltrating gamma delta cells showed effector memory and terminally-differentiated phenotypes and, accordingly, polyclonal gamma delta T cell lines obtained from tumor-infiltrat…

MelanomasCytotoxicity ImmunologicMaleRENAL-CELL CARCINOMA OVERCOMING IMMUNOLOGICAL-TOLERANCE METASTATIC MELANOMA TUMOR-CELLS PHASE-I MEVALONATE PATHWAY TARGETING CTLA-4 LYMPH-NODES IMMUNOTHERAPY CANCERAnatomy and PhysiologySkin NeoplasmsTUMOR-CELLSLymphocytemedicine.medical_treatmentT-LymphocytesSettore MED/19 - Chirurgia PlasticaTARGETING CTLA-4Interleukin 21T-Lymphocyte SubsetsImmune PhysiologyMETASTATIC MELANOMACytotoxic T cellIL-2 receptorSkin TumorsMelanomaOVERCOMING IMMUNOLOGICAL-TOLERANCEAged 80 and overMultidisciplinaryT CellsMelanomaMalignant MelanomaQRReceptors Antigen T-Cell gamma-deltaMiddle AgedCANCERPHASE-Imedicine.anatomical_structureCytokinePhenotypeOncologyCytokinesMedicineFemaleResearch ArticleTumor ImmunologyAdultScienceT cellImmune CellsImmunologyMalignant Skin NeoplasmsDermatologyBiologyImmunophenotypingImmune systemLymphocytes Tumor-InfiltratingmedicineHumansIMMUNOTHERAPYBiologyAgedNeoplasm StagingSettore MED/04 - Patologia GeneraleLYMPH-NODESCancers and NeoplasmsImmunologic Subspecialtiesmedicine.diseaseImmune SystemImmunologyOVERCOMING IMMUNOLOGICAL-TOLERANCE; METASTATIC MELANOMA; TUMOR-CELLS; PHASE-I; MEVALONATE PATHWAY; TARGETING CTLA-4; LYMPH-NODES; IMMUNOTHERAPY; CANCERClinical ImmunologyImmunologic MemoryMEVALONATE PATHWAYPLoS ONE
researchProduct

Phase-Imaging Ion-Cyclotron-Resonance technique at the JYFLTRAP double Penning trap mass spectrometer

2018

The Phase-Imaging Ion-Cyclotron-Resonance (PI-ICR) technique has been commissioned at the JYFLTRAP double Penning trap mass spectrometer. This technique is based on projecting the ion motion in the Penning trap onto a position-sensitive multichannel-plate ion detector. Mass measurements of stable 85 Rb $ ^{+}$ and 87 Rb $ ^{+}$ ions with well-known mass values show that relative uncertainties $ \Delta m/m \leq 7\cdot 10^{-10}$ are possible to reach with the PI-ICR technique at JYFLTRAP. The significant improvement both in resolving power and in precision compared to the conventional Time-of-Flight Ion Cyclotron Resonance technique will enable measurements of close-lying isomeric states and …

Nuclear and High Energy PhysicstutkimuslaitteetHadronCyclotronspektrometritdouble penning trap mass spectrometerMass spectrometry01 natural sciencesIonlaw.inventionPhysics::Plasma Physicslaw0103 physical sciencesJYFLTRAPNuclear fusionNuclear Experiment010306 general physicsPhysics010308 nuclear & particles physicssyklotronitPenning trapphase-imagingion-cyclotron-resonance techniqueNeutrinoAtomic physicsydinfysiikkaIon cyclotron resonanceThe European Physical Journal A
researchProduct

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy

2010

Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients eligible for second-line treatment is scarce. The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival.Methods: individual data from nine randomised trials of second-line treatment in advanced NSCLC were analysed. Primary end-point was overall survival (OS). Cox model, stratified by trial, was used for multivariate analyses, and a prognostic index was provided and validated according to an internal/external procedure.Results: Out of 1239 patients, 119…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisLung NeoplasmsWEEKLY DOCETAXELIRINOTECANCOMBINATION CHEMOTHERAPYAntineoplastic AgentsERLOTINIBPrognostic factorsNSCLCTHERAPYPooled analysisPLUS GEMCITABINEInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Lung cancerEVERY 3 WEEKSAgedNeoplasm StagingRandomized Controlled Trials as TopicAged 80 and overPerformance statusProportional hazards modelbusiness.industryAge FactorsCombination chemotherapyPHASE-III TRIALMiddle Agedmedicine.diseasePrognosisTreatment OutcomeOncologyMeta-analysisPrognostic scoreCOMPARING DOCETAXELSecond-line treatmentAdenocarcinomaFemalebusinessEpidemiologic MethodsNon-small-cell lung cancerEuropean Journal of Cancer
researchProduct

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: prelimi…

2006

Abstract Background The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned. Methods Patients with ovarian cancer (stage Ic-IV), aged 2, every 3 weeks or to carboplatin AUC 5 plus pegylated liposomal doxorubicin 30 mg/m2, every 3 weeks. Treatment was planned for 6 cycles. Toxicity was coded according to the NCI-CTC version 2.0. Results The pre-planned safety analysis was performed…

OncologyCancer Researchendocrine system diseasesSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPACLITAXELlaw.inventionPolyethylene Glycolschemistry.chemical_compoundRandomized controlled trialSTAGE-IIIlawCYCLOPHOSPHAMIDEAntineoplastic Combined Chemotherapy ProtocolsOvarian NeoplasmsSTERICALLY STABILIZED LIPOSOMESMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality Therapyfemale genital diseases and pregnancy complicationsPaclitaxelOncologyMITO-2 randomized trialcarboplatinSURVIVALFemaleChemical and Drug Induced Liver Injurymedicine.drugAgranulocytosisResearch ArticleAdultmedicine.medical_specialtyCARCINOMAOvariectomylcsh:RC254-282Drug Administration ScheduleDrug HypersensitivityCISPLATINpreliminary resultInternal medicinemedicineGeneticsXENOGRAFTSHumansDoxorubicinParesthesianeoplasmsMETAANALYSISAgedChemotherapybusiness.industryAlopeciamedicine.diseasePHASE-IIIThrombocytopeniaCarboplatinSurgeryClinical trialchemistryDoxorubicinLiposomesFeasibility StudiesTopotecanOvarian cancerbusinessBMC Cancer
researchProduct

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

2017

Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for …

PathologyNeoplasm ResidualInternational CooperationDiseaseReview ArticleBiochemistryEuropean LeukemiaNet0302 clinical medicineRisk Factorshemic and lymphatic diseasesCONVENTIONAL CARE REGIMENSDisease management (health)medicine.diagnostic_testACUTE MYELOGENOUS LEUKEMIAHematopoietic Stem Cell TransplantationDisease ManagementSINGLE CEBPA MUTATIONSHematology1ST COMPLETE REMISSIONHIGH-DOSE CYTARABINELeukemia Myeloid AcuteTreatment Outcome030220 oncology & carcinogenesisPractice Guidelines as TopicAdultmedicine.medical_specialtyConsensusImmunologyBUSULFAN PLUS CYCLOPHOSPHAMIDEMEDLINEMINIMAL RESIDUAL DISEASEAntineoplastic AgentsACUTE MYELOID-LEUKEMIAEnasidenibTransplantation AutologousDrug Administration ScheduleImmunophenotyping03 medical and health sciencesmedicineHumansGenetic TestingIntensive care medicineGenetic testingbusiness.industrySTEM-CELL TRANSPLANTATIONCell BiologyRANDOMIZED PHASE-IIIMinimal residual diseaseTransplantationbusinessSettore MED/15 - Malattie del Sangue030215 immunology
researchProduct